Immunotoxicology Specialty
Section Newsletter
P re s i d e n t ’s M e s s a g e
Rodney Dietert, Ph.D.
I hope that your holiday season has been filled with
useful reflections, joy and visions of a wonderful 2012.
This newsletter message will be uncharacteristicallybrief, yet will target some areas for possible attention.
2011 - 2012
Executive Committee
President
Dr. Rodney R. Dietert
Vice President
Dr. Greg Ladics
Vice President-Elect
Dr. Gary Burleson
Secretary-Treasurer
Dr. Susan McKarns
Past President
Dr. Leigh Ann Burns Naas
Senior Councilor
Dr. Kazuichi Nakamura
Junior Councilor
Dr. Jean Pfau
PostDoc Representative
Dr. Teri Girtsman
Student Representative* Position OpenThe ImTox SS Newsletter is published 3times/year (May, September and January). If
you would like to share a book review,
meeting report, interesting web site or any
other item of interest with members of theSpecialty Section, please send it to us by the
middle of the month preceding the planned
publication date. All comments on, or
suggestions for, the newsletter are welcome.
Communications Committee Co-Chairs
Haley Neff-LaFord, PhD:
hnlaford@seagen.com
Ashwini Phadnis:
phadnisa@msu.edu
Typesetting / desktop publishing provided by
L. Peyton Myers, Ph.D.

January 2012

Preparations for San Francisco and San Antonio
As we usher in the new year I would encourage you to
finalize any nominations of students, postdocs, and Dr. Rodney Dietert
colleagues that might still be open for SS and SOT President, ImTox SS
awards and send Gary Burleson and the Program
2011-2012
Committee your best ideas for symposia, workshops,
round tables and continuing education courses for the 2013 meeting in San
Antonio. Planning ahead is very useful to ensure that our best work is on
display and given appropriate recognition in both San Francisco and San
Antonio.
Our ImTox SS reception at SOT in San Francisco has been scheduled for
Tuesday evening from 6:00PM-7:30PM. I hope to see as many of you as ispossible at this event.
The New Terrain of Immunotoxicology
The current year 2011-12 continues to be one of a tangible repositioning of thelandscape of immunotoxicology within the biomedical and health-associatedcommunities. This shift stems from a combination of both previously-planned
activities and more recent developments. Regardless of the nature of your own
personal work related to immunotoxicology (fundamental research, safetyassessment, immunopharmacology, education, risk assessment, regulatory
review, etc.), the implications of your work just got a type of free upgrade. Of
course, there are no assurances that this “significance of your work” upgrade
will be automatically reflected in your next paycheck.

President’s Message.........................................................................page 1
Committee Updates ....................................................................page 2 - 4
SOT 2012 Program Updates ...........................................................page 5
ImTox SS Financial Reports (current and prior years)........ pages 6 - 7
Advertisements/Announcements....................................................page 8
Articles of Interest ...........................................................................page 9

1

Immunotoxicology Specialty Section

At the core of this sea change is a
shift from a more historic view of:1)
immunotoxicology
ascalibration and organization of
measureable immune endpoints
that have generalized health
implications to 2) immunotoxicology
asapriority
benchmark for determining therisk of quite specific andnumerous major diseases andconditions.
In particular, thisincludes the arena of noncommunicable chronic diseases.
The reason the linkage between
immunotoxicity
andchronic
diseases is garnering increased
attention is that chronic diseases
are the leading cause of deathworldwide. Additionally, the costof chronic diseases is expected toreach a staggering 48% of the
global gross domestic product by
the year 2030 (World Economics
Council and the Harvard Schoolof Public Health). Last month’s
STEP Symposium broadcast
across the National Institutes of
Health set a template for theconnection between immunotoxicity, immune dysfunction,
inflammatory misregulation andchronic diseases across thevarious grant panels and theassociated biomedical researchcommunities connected to the
NIH. This symposium preceded asoon-to-be-releasedbook(Springer) on the same topic thatis notable in that the diseasespecific chapters of the book wereauthored by a preponderance of
non-immunotoxicologists.
Therefore, the immunotoxicityspecific disease connection has
rippled well beyond our SS and
SOT to the broader scientificcommunity. Next spring’s SOTcosponsored
CCT
meeting,
ppTOX III, in Paris includes an
opening-day session chaired by
Dr. Paige Lawrence that focuseson early life environmental
exposuresandlife-long
immunological programming. It
is likely to expand our new
immunotoxicology terrain evenfurther.
A Distinctive Honor
One of our ImTox SS members,
Dr. Ian Kimber, recently received
an honor that, to my knowledge, is
a
first
among
immunotoxicologists. At Queen Elizabeth
II’s most recent birthday, Dr.
Kimber had bestowed upon him
the honor of the Order of the
British Empire (OBE). The OBE

is a title awarded across thesciences,arts,
humanities,
humanitarian, and public service
arenas for a select subset ofindividuals who have madeextraordinary achievements benefitting society.
This highlyselective group of notable
individuals is drawn from acrossGreat
BritainandtheCommonwealth countries basedon their remarkable career
accomplishments.
Dr. Kimber
joins
other
OBE-titledtoxicologists such as Drs. Philip
Routledge, Andrew Renwick,
Roy Goulding, Tim Marrs, Alan
Boobis and Len Levy.
Other
2011 awardees who joined Dr.
Kimber in this special recognition
included: Colin Firth - actor, Dr.
David William Roger Thackray Head of Archaeology, National
Trust, Ian Robert Whitting - HM
Ambassador to Iceland, and Ms
Elizabeth Ann MacGregor Director, Museum of Contemporary Art, Sydney, Australia.
I invite you to join me in offering
three cheers to Ian for this welldeserved and distinguished career
honor.
Rodney Dietert

Regulatory Update
Submitted by: Peter Thomas, Regulatory Subcommittee Chair.
The following regulatory updates may be of interest to the Specialty Section Membership.
According to the California Department of Toxic Substances Control, Immunotoxicity was included as one ofnine specific hazards listed in an “informal draft” Safer Consumer Products regulation that would use a 0.01%
hazard threshold. The others were carcinogenicity, developmental toxicity, reproductive toxicity, endocrine
toxicity, genotoxicity, neurotoxicity, bioaccumulation, or environmental persistence. This hazard threshold is
lower than the current generally applied 0.1% level used under United Nations Globally Harmonized Systems
for classification, where immunotoxicity does not have a specific hazard classification.
January 20122

Immunotoxicology Specialty Section

A request (via the Federal Register Vol. 76, No. 224) for publiccomments was issued by National
Institute of Environmental Health
Sciences and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods as
they look to update their FiveYear Plan (current plan runs 20082012).
They specifically mentioned immunotoxicity as a priority testing area
Recently, the EMA published aconcept paper that will be used todraft the revision for the Guidelineon Similar Biological Medicinal
Products Containing Biotechnology Derived Proteins as Active
Substance: Non-clinical and ClinicalIssues(CHMP/
BMWP/42832/2005). This guideline describes the nonclinical andclinical requirements for a biological medicinal product claiming to be similar to another one
already marketed and came into
effect in 2006. Since then, the development of biosimilar products
has increased significantly and theregulatory framework is becoming
larger. The comment period deadline is 31 December 2011. The
draft guideline is expected to be
published in 2012.
Website:http://www.ema.europa.eu/docs/
en_GB/document_library/
Scientific_guideline/2011/10/
WC500115611.pdf

January 2012

The International Conference on
Harmonization (ICH) Steering
Committee hosted a meeting with
its working groups in Seville,
Spain from 05 November – 10
November 2011.
The revised“ICH S2(R1) Guideline forgenotoxicity testing and data interpretation for medicines intended for human use” received
approval.
Website: http://
www.ich.org/ichnews/pressreleases/view/article/ich-steeringcommittee-seville-spain-9-10november-2011-1.html
The FDA recently published a
guidance document on integrating
study results to assess concerns
about reproductive and developmental toxicity. This new FDA
guidance outlines a process to estimate developmental or reproductive risks associated with a new
drug when there is a non-clinical
toxicity finding but no definitive
human data. While immunotoxicity is not considered one of thefour major manifestations of developmental immunotoxicity, it
may play a role in a weight of evidence approach to risk assessment. Website: http://
www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM079240.pdf

Student andPostdoctoral
ReportSubmitted by: Teri Girtsman,
Postdoctoral Representative
Greetings to all student andpostdoctoral members of the
ImTox SS!
I hope that theapproaching New Year finds you
with an abundance of wonderfulscience to share at the upcoming
SOT Annual meeting March 6-10
in San Francisco, the beautiful
city by the bay.
A reminder to the graduate
students the Student Advisory
Council (SAC) has been
restructured as the Graduate
Student Leadership Committee(GSLC). The GSLC is comprisedof an executive board and threesubcommittees (communications,professional development, andprogramming) that are comprisedof the graduate student reps for
special sections, special interest
groups, and regional chapters. If
you have any ideas that would be
beneficial for your careerdevelopment or activities for theannual meeting, feel free tocontact me so that I may relay
your thoughts to the executive
board!
Congratulations to the newly
minted postdoctoral fellow Jenna
Benson Ph.D. who successfully
defended her dissertation at the
University of Montana on

3

Immunotoxicology Specialty Section

December 9. Thank you for theservice you provided the ImTox
SS as the student rep this year! To
this end, we are now in search fora student representative to fill the
spot left behind by Dr. Benson.
For those interested in thisposition, please send your CV, abrief letter describing yourresearch goals, and a nomination
letter from your advisor to Dr.
Rodney Reynolds Dietert(rrd1@cornell.edu) . You should
first verify with your advisor thathe/she is willing to fund yourtravel to SOT for the next two
years. Please do not hesitate tocontact former student rep, Jenna
Benson (jenna.benson@umontana.edu) or Teri Girtsman(teri.girtsman@umontana.edu) for

more information about serving asa student representative.
We would like to thank the SOT
for making available – “K99-R00
GRANTS: Tips from the NIEHS
Administrator, the Grantee and the
Reviewer”, Postdoctoral
Assembly Web Seminar that took
place on October 31st. It was wellattended and extremely helpful todevelop strategies to prepare forsuccessful NIH grant submission
and ultimately successful funding.
The slides are available on“toXchange” at http://
www.toxicology.org/ai/spd/PD/
seminarOct11.asp.
Don’t miss the opportunity tosocialize at the 2012 meeting in
San Francisco (details to follow)!

I look forward to meeting you atthe 2012 mixer. Come kick backand relax with fellow ImTox SS
students and postdocs. It’s
guaranteed to be a good time! Any
and all suggestions about this orother types of student/postdoc
events are welcome. Don’t
hesitate to contact me (TeriGirtsman PDR).
Again, we would like to thank you
for this opportunity to serve you.
Please let us know about any
concerns or suggestions you may
have on how the ImTox SS canbestassistyouas
immunotoxicology students andpostdoctoral fellows!
I lookforward to hearing from you!
Postdoctoral Representative, Teri
Alyn Girtsman Ph.D.

At the time of publication, the
ImTox SS reception is scheduled
for the evening of Tuesday
March,13.
Please check the final
Program for final location.

January 2012

4

SOT

Immunotoxicology Specialty Section

IEC Notes
Submitted by: Mitchell Cohen
The International Exchange Committee (IEC) is pleased to announce that the invited JSIT representative for
San Antonio, 2013 - Dr. Hirohisa Takano (Environmental Health Division, Department of Environmental
Engineering, Graduate School of Engineering, Kyoto University and Past Director at the Environmental Health
Sciences Division, National Institute for Environmental Studies - and Dr. Jean Pfau (Idaho State University,
Pocatello, ID) are putting together a Symposium on “Global/Local Environmental Changes and Immune
Alteration”. We look forward to this and continuing future jointly chaired sessions generated by members ofboth of our societies.
The IEC is also pleased to announce that one IMTOX SS member would speak at the upcoming JSIT 2012
meeting to be held at the Jikei University School of Medicine, Tokyo, in September (9/15-16/12). Based on themeeting’s theme of “New Frontiers in Immunotoxicology", Dr. Henk van Loveren has been invited to speak to
the JSIT membership on this very important topic. To see all of the presentations at the upcoming meeting, as
well as to see presentation topics and pix from all past meetings (including of our former attendees), please go
to the JIST site at http://www.immunotox.org/english/index.html.

SOT 2012 Program Updates
Submitted by: Greg Ladics
From Greg Ladics:
The Immunotoxicology Specialty Section will be well represented at the 2012 meeting in San Francisco with a
total of 7 sessions (2 CE courses, 3 symposia and 2 workshops). These sessions include the following:
CE Course entitled “Overview and Application of the WHO/IPCS Harmonized Guidance for Immunotoxicity
Risk Assessment for Chemicals”; Chairs- Andrew Rooney and Henk van Loveren
CE Course entitled “Innate Immunity and Its Relevance to Toxicology”; Chairs – Wendy Freebern andJacintha Shenton.
Symposium - “The Allergenicity and Immunomodulatory Effect of Food Substances”; Chairs- Greg Ladics
and Reiko Teshima
Symposium - “The Role of Danger Signals in the Development of Chemical Sensitization by Environmental
and Occupational Agents”; Chairs- Marc Pallardy and Raymond Pieters
Symposium - “Nanoparticles for Drug Delivery: Interactions with the Immune System”; Chairs- Sandra
Casinghino and Marina Dobrovolskaia
Workshop - “Therapeutic Immunomodulation and Cancer Risk: Science, Risk Assessment, and Risk
Communication”; Chairs- Marc Pallardy and Shawn Heidel
Workshop - “T-Dependent Antibody Responses in Nonhuman Primates: Challenges and Opportunities”;
Chairs- Jacintha Shenton and Herve Lebrec
January 20125

Immunotoxicology Specialty Section

Financial Report for 2010-2011
Submitted by: Susan McKarns
The fiscal year runs for 12 months ending on June 30th

Financial Statement

2010‐2011

IncomeContributions
Dues

‐
5,010

Misc. Income
Registration‐‐aInterest

513b

Total Income

9.839

ExpenseAwards ‐ Sections
Plaques
Contribution

(100)
759
966

Executive Meetings‐

Miscellaneous
Newsletter

715‐

Reception
Symposia
TravelWeb Development

4.816
‐
‐
‐

Total Expense

d

7,156

Excess (Deficiency) of
Revenue over Expenses

2,683

Net Assets Beginning of year

8.081

Net Assets End of Year

10,764January 2012c

6

Immunotoxicology Specialty Section

Financial Report for 2009-2010
Submitted by: Susan McKarns
The fiscal year runs for 12 months ending on June 30th

Financial Statement

2009‐2010

IncomeContributions
Dues

900
5,070

Registration
Interest

3,642
385

a

Global Initiatives Matching Funds

2,000

b

Total Income

11,997

ExpenseAwardsPlaques (Accent Engraving)
Executive Meetings

1,550
760
0

c

Miscellaneous
Newsletter
Reception

1,082
300
9,798

d

Total Expense

13,490

Excess (Deficiency) of
Revenue over Expenses(1,493)

Net Assets Beginning of year

9,574

Net Assets End of Year

8,081

a

Registration income reflects an allocation of funds from SOT based on the number of our members that attended the 2010
SOT Annual Meetingb$2000 awarded to ImTox SS to support our International exchange with the JSIT

c$1000 to be credited to 2010‐2011 fiscal year due to an errordIncludes expenses such as the ImTox Pool of Lecturer's, Student/Postdoc mixer, International Exchange, extras for the 25th
Anniversary celebration

January 20127

Immunotoxicology Specialty Section

Announcements

January 20128

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Compiled by Haley Neff-LaFord
Note: The Communications Committee has changed their policy on epub inclusion. Any article that isfully available electronically (i.e. has a doi) can now be included.
ANYTIME you have a fully published or electronically-available article to report, please send it to thecoordinator, Haley Neff-LaFord: hnlaford@seagen.com

Asthma, Allergy, Autoimmunity & Hypersensitivity
de Jong HJ, Cohen Tervaert JW, Saldi SR, Vandebriel RJ, Souverein PC, Meyboom RH, van Loveren H and
Klungel OH. Association between statin use and Lupus-like syndrome using spontaneous reports. Semin
Arthritis Rheum 41:373-381, 2011.
de Jong HJ, Klungel OH, Van Dijk L,Vandebriel RJ, Leufkens HGM, van der Laan JW, Cohen Tervaert JW
and van Loveren H. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis
2011 Oct 6 Epub ahead of print; PMID: 21979000, 2011.
Franko J, Jackson LG, Hubbs A, Kashon M, Meade BJ and Anderson SE. Evaluation of furfuryl alcohol
sensitization potential following dermal and pulmonary exposure: enhancement of airway responsiveness.
Toxicol Sci 125:105-115, 2012.
Hennen J, Aeby P, Goebel C, Schettgen T, Oberli A, Kalmes M and Blömeke B. Cross talk between
keratinocytes and dendritic cells: impact on the prediction of sensitization. Toxicol Sci 123:501-510, 2011.
Johnson VJ, Reynolds JS, Wang W, Fluharty K and Yucesoy B. Inhalation of ortho-phthalaldehyde vaporcauses respiratory sensitization in mice. J Allergy (Cairo). 011;2011:751052. Epub 2011 Jul 14. PubMed
PMID: 21785612; PubMed Central PMCID: PMC3137992.
Liu D, Zheng Y, Li B, Yao H, Li R, Zhang Y and Yang X. Adjuvant effects of gaseous formaldehyde on thehyper-responsiveness and inflammation in a mouse asthma model immunized by ovalbumin. J Immunotoxicol
8:305-314, 2011.
Mustafa A, Holladay SD, Witonsky S, Kerr R, Reilly C, Zimmerman K, Manari A, Countermarsh S and Gogal
RM Jr. Prenatal TCDD causes persistent modulation of the postnatal immune response, and exacerbates
inflammatory disease, in 36-week-old lupus-like autoimmune SNF1 mice. Birth Defects Res B Dev Reprod
Toxicol 92:82-94, 2011.
Marchand LS, St-Hilaire S, Putnam EA, Serve KM and Pfau JC. Mesothelial cell and anti-nuclear
autoantibodies associated with pleural abnormalities in an asbestos exposed population of Libby MT. Toxicol
Lett 208:168-173, 2012.
Patil SD, Patel MR, Patel SR and Surana SJ. Amaranthus spinosus Linn. inhibits mast cell-mediatedanaphylactic reactions. J Immunotoxicol 2012 early on-line DOI: 10.3109/1547691X.2011.631609.
Pot LM, Alizadeh BZ, Ahrenberg D, Coenraads PJ, Snieder H and Blömeke B. No major role for glutathione
S-transferase gene polymorphisms in sensitization to para-phenylenediamine and other xenobiotics: a study of
association and a meta-analysis. Br J Dermatol 164:890-892, 2011.

January 20129

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Rees B, Spiekstra SW, Carfi M, Ouwehand K, Williams CA, Corsini E, McLeod JD and Gibbs S. Interlaboratory study of the in vitro dendritic cell migration assay for identification of contact allergens. Toxicol In
Vitro 25:2124-2134, 2011.
Shaw FL, Cumberbatch M, Kleyn CE, Begum R, Dearman RJ, Kimber I and Griffiths CEM. Langerhans cell
mobilization distinguishes between early-onset and late-onset psoriasis. J Invest Derm 130:1940-1942, 2010.
Vandebriel RJ, Callant Cransveld C, Crommelin D, Diamant Z, Glazenburg B, Joos G, Kuper F, Natch A,
Nijkamp F, Noteborn H, Pieters RD, Roggen E, Rorije E, Seed M, Sewald K, van den Heuvel R, van Engelen
J, Verstraelen S and van Loveren H. Respiratory sensitization: Advances is assessing the risk of respiratory
sensitization and irritation. Toxicol in Vitro 25:1251-1258, 2011.
Yucesoy B and Johnson VJ. Genetic variability in susceptibility to occupational respiratory sensitization. J
Allergy (Cairo). 011;2011:346719. Epub 2011 Jun 12. PubMed PMID: 21747866; PubMed Central PMCID:
PMC3124895.

Developmental Immunotoxicology
Allina J, Grabowski J, Doherty-Lyons S, Fiel MI, Jackson CE, Zelikoff JT and Odin JA. Maternal allergy acts
synergistically with cigarette smoke exposure during pregnancy to induce hepatic fibrosis in adult maleoffspring. J Immunotoxicol 8:258-264, 2011.
Holladay SD, Mustafa A and Gogal RM Jr. Prenatal TCDD in mice increases adult autoimmunity. Reprod
Toxicol 92:82-94, 2011.
Horváthová M, Jahnová E, Palkovičová L, Trnovec T and Hertz-Picciotto I. Dynamics of lymphocyte subsets
in children living in an area polluted by polychlorinated biphenyls. J Immunotoxicol 8:333-345, 2011.
Horváthová M, Jahnová E, Palkovičová L, Trnovec T and Hertz-Picciotto I. The kinetics of cell surface
receptor expression in children perinatally exposed to polychlorinated biphenyls. J Immunotoxicol 8:367-380,
2011.
Mustafa A, Holladay SD, Witonsky S, Reilly C, Sponenberg DP and Gogal RM Jr. A single mid-gestation
exposure of C57BL/6 mice to TCDD causes permanent postnatal shifts toward an autoreactive immune
phenotype. Toxicology 290:157-169, 2011.
ul-Hassan Z, Khan MZ, Khan A, Javed I and Noreen M. In vivo and ex vivo phagocytic potential ofmacrophages from progeny of breeder hens kept on ochratoxin A (OTA)-contaminated diet. J Immunotoxicol
2012 early on-line DOI: 10.3109/1547691X.2011.635349.
ul Hassan Z, Khan MZ, Saleemi MK, Khan A, Javed I and Noreen M. Immunological responses of male White
Leghorn chicks kept on ochratoxin A (OTA)-contaminated feed. J Immunotoxicol 2012 early on-line DOI:
10.3109/1547691X.2011.627393.
Schaalan MF, Abdelraouf SM, Mohamed WA and Hassanein FS. Correlation between maternal milk andinfant serum levels of chlorinated pesticides (CP) and the impact of elevated CP on bleeding tendency andimmune status in some infants in Egypt. J Immunotoxicol 2012 early on-line DOI:
10.3109/1547691X.2011.606432.
January 201210

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Effects: Compounds
Amirghofran Z, Hashemzadeh R, Javidnia K, Golmoghaddam H and Esmaeilbeig A. In vitro
immunomodulatory effects of extracts from three plants of the Labiatae family and isolation of the active
compound(s). J Immunotoxicol 8:265-273, 2011.
Banton MI, Peachee VL, White KL, Jr. and Padgett EL. Oral subchronic immunotoxicity study of ethyl
tertiary butyl ether in the rat. J Immunotoxicol 8:298-304, 2011.
Ben Sghaier M, Krifa M, Mensi R, Bhouri W, Ghedira K and Chekir-Ghedira L. In vitro and in vivo
immunomodulatory and anti-ulcerogenic activities of Teucrium ramosissimum extracts. J Immunotoxicol
8:288-297, 2011.
Carignan D, Désy O and de Campos-Lima PO. The dysregulation of the monocyte/macrophage effector
function induced by isopropanol is mediated by the defective activation of distinct members of the AP-1
family of transcription factors. Toxicol Sci 125:144-156, 2012.
Corsini E, Sangiovanni E, Avogadro A, Galbiati V, Viviani B, Marinovich M, Galli CL, Dell'agli M andGermolec DR. In vitro characterization of the immunotoxic potential of several perfluorinated compounds(PFCs). Toxicol Appl Pharmacol. 2011 Nov 18. [Epub ahead of print]
Galbiati V, Carne A, Mitjans M, Galli CL, Marinovich M, Corsini E. Isoeugenol destabilizes IL-8 mRNA
expression in THP-1 cells through induction of the negative regulator of mRNA stability tristetraprolin. Arch
Toxicol. 2011 Oct 4. [Epub ahead of print] PMID: 21969073
Guilbert C, Kelly AD, Petruccelli LA, Lemaire M, Mann KK. Exposure to tungsten induces DNA damage andapoptosis in developing B lymphocytes. Leukemia 2011Jun 24. doi: 10.1038/leu.2011.160. [Epub ahead ofprint] PMID:21701490
Guo TL, Germolec DR, Collins BJ, Luebke RW, Auttachoat W, Smith MJ and White KL Jr.
Immunotoxicological profile of chloramine in female B6C3F1 mice when administered in the drinking waterfor 28 days. J Immunotoxicol. 8:381-388, 2011.
Hsiao CL, Wu KH and Wan KS. Effects of environmental lead exposure on T-helper cell-specific cytokines inchildren. J Immunotoxicol 8:284-287, 2011.
Inada T, Kubo K, Ueshima H and Shingu K. Intravenous anesthetic propofol suppresses prostaglandin E2
production in murine dendritic cells. J Immunotoxicol 8:359-366, 2011.
Katika MR, Hendriksen PJM, van Loveren H and Peijnenburg A. Exposure of Jurkat cells to bis(tri-n-butyltin)oxide (TBTO) indices transcriptomics changes indicative for ER- and oxidative stress, T cell activation, andapoptosis. Toxicol Appl Pharmacol 254:311-322, 2011.
Lu J, Jones AD, Harkema JR, Roth RA and Ganey PE. Amiodarone exposure during modest inflammationinduces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci 125:126-133,
2012.
McMahon L, Schwartz K, Yilmaz O, Brown E, Ryan LK and Diamond G. Vitamin D-mediated induction of
innate immunity in gingival epithelial cells. Infect Immun 79:2250-2256, 2011.

January 201211

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Nyland JF, Fairweather D, Shirley DL, Davis SE, Rose NR and Silbergeld EK. Low-dose inorganic mercury
increases severity and frequency of chronic coxsackievirus-induced autoimmune myocarditis in mice. Toxicol
Sci 125:134-143, 2012.
Nyland JF, Fillion M, Barbosa F Jr, Shirley DL, Chine C, Lemire M, Mergler D and Silbergeld EK.
Biomarkers of methyl mercury exposure immunotoxicity among fish consumers in Amazonian Brazil. Environ
Health Persp 119:1733-1738, 2011.
Palmer RK, Hutchinson LM, Burpee BT, Tupper EJ, Pelletier JH, Kormendy Z, Hopke AR, Malay ET, Evans
BL, Velez A and Gosse JA. Antibacterial agent triclosan suppresses RBL-2H3 mast cell function. Toxicol
Appl Pharmacol doi: 10.1016/j.taap.2011.10.012, 2011.
Park M, Neigh AM, Vermeulen JP, de la Fonteyne LJJ, Verharen HW, Briede JJ, van Loveren H and De Jong
W. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity ofsilver nanoparticles. Biomaterials 32:9810-9817, 2011.
Rasmussen DL and Pfau JC. Asbestos activates CH12.LX B-lymphocytes via macrophage signaling. J
Immunotoxicol 2012 early on-line DOI: 10.3109/1547691X.2011.631953.
Rigo I , McMahon L, Dhawan P, Christakos S, Yim S, Ryan LK and Diamond G. Induction of triggering
receptor expressed on myeloid cells (TREM-1) in airway epithelial cells by 1,25(OH)2 Vitamin D3. Innate
Immun (Epub ahead of print 2011 June 20). PMID: 21690199
Sandeep Varma R, Ashok G, Vidyashankar S, Nandakumar KS and Patki PS. Bresol inhibits
phosphodiesterase 4 gene expression and modulates the levels of select mediators of inflammation in humanmonocytic cells. J Immunotoxicol 8:315-323, 2011.
Siveen KS and Kuttan G. Effect of Aerva lanata on cell-mediated immune responses and cytotoxic Tlymphocyte generation in normal and tumor-bearing mice. J Immunotoxicol 2012 early on-line DOI:
10.3109/1547691X.2011.609191.\

General Immunotoxicology
Buoso E, Lanni C, Molteni E, Rousset F, Corsini E and Racchi M. Opposing effects of cortisol anddehydroepiandrosterone on the expression of the receptor for Activated C Kinase 1: implications in
immunosenescence. Exp Gerontol 46:877-883, 2011.
Heo Y, Zhang Y, Gao D, Miller VM and Lawrence DA. Aberrant immune responses in a mouse withbehavioral disorders. PLoS One 6(7):e20912. PMID: 21799730, 2011.
Jakopin Ž, Corsini E, Gobec M, Mlinarič-Raščan I and Dolenc MS. Design, synthesis and biologicalevaluation of novel desmuramyldipeptide analogs. Eur J Med Chem 46:3762-3777, 2011.
Kalmes M, Hennen J, Clemens J and Blömeke B. Impact of aryl hydrocarbon receptor (AhR) knockdown oncell cycle progression in human HaCaT keratinocytes. Biol Chem 392:643-51, 2011.
Lebrec H, O’Lone R, Freebern W, Komocsar W and Moore P. Survey: Immune function and immunotoxicity
assessment in dogs. J Immunotoxicol 2012 early on-line DOI: 10.3109/1547691X.2011.592163.
January 201212

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Mittal N and Sanyal SN. In vivo effect of surfactant on inflammatory cytokines during endotoxin-induced lunginjury in rodents. J Immunotoxicol 8:274-283, 2011.
Park SH, Choi HJ, Do KH, Yang H, Kim J and Moon Y. Chronic Nod2 stimulation potentiates activatingtranscription factor 3 and paradoxical superinduction of epithelial proinflammatory chemokines by mucoactive
ribotoxic stressors via RNA-binding protein human antigen R. Toxicol Sci 125:116-125, 2012.
Ryan LK, Dai J, Yin Z, Megjugorac N, Uhlhorn V, Yim S, Schwartz KD, Diamond G and Fitzgerald-Bocarsly
PA. Modulation of human ß-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes andepithelial cells by influenza virus, Herpes simplex virus and Sendai virus and its possible role in innate
immunity. J Leuk Biol 90:343-358, 2011.
Salawu MO and Oloyede OB. Endotoxin-induced coagulation reactions and phenoloxidase activity modulationin Sudanonautes africanus hemolymph fractions. J Immunotoxicol 8:324-332, 2011.
Zhou R, Lai Y, Yamabe N, Fukui M and Zhu BT. Estriol has different effects from 17β-estradiol inmodulating mouse splenocyte function under inflammatory conditions. J Immunotoxicol 8:346-358, 2011.

Methods
Dhir V, Fort M, Mahmood A, Higbee R, Warren W, Narayanan P and Wittman V. A predictive biomimetic
model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J
Immunotoxicol 2012 early on-line DOI: 10.3109/1547691X.2011.613419.
Klein SG, Hennen J, Serchi T, Blömeke B and Gutleb AC. Potential of coculture in vitro models to study
inflammatory and sensitizing effects of particles on the lung. Toxicol In Vitro 25:1516-1534, 2011.
Marusov GP, Sweatt AJ, Pietrosimone K, Benson DR, Geary SJ, Silbart LK, Challa S, Lagoy J, Lawrence DA
and Lynes M. A microarray biosensor for multiplexed detection of microbes using grating-coupled surface
plasmon resonance imaging. Environ Sci Technol doi:10.1021/es201239f ?, 2011.
Pronk T, van der Veen J, Ezendam J, Van Loveren H and Pennings J. Effects of pooling RNA from samples
treated with different compounds for determining class-specific biomarkers and processes in toxicogenomics.
Toxicol In Vitro 25:1841-1847, 2011.
Ruwona TB, Johnson VJ, Hettick JM, Schmechel D, Beezhold D, Wang W, Simoyi RH and Siegel PD.
Production, characterization and utility of a panel of monoclonal antibodies for the detection of toluene
diisocyanate haptenated proteins. J Immunol Methods 373:127-35, 2011.

Neurotoxicology
Graber DJ, Snyder-Keller A, Lawrence DA and Turner JN. Neurodegeneration by activated microglia across ananofiltration membrane. J Biochem Molec Toxicol doi:10.1002/jbt.20384. PMID: 21308894, 2011.

January 201213

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Reviews/Workshops/Editorials
Basketter DA and Kimber I. Assessing the potency of respiratory allergens: uncertainties and challenges.
Regul Toxicol Pharmacol 61:365-372, 2011.
Basketter DA and Kimber I. Skin irritation, false positives and the local lymph node assay: a guideline issue?
Regul Toxicol Pharmacol 61:137-140, 2011.\
Basketter D, Kimber I, van Loveren H, Pallardy M and Warheit D. Progress (from 2005-2008) and remaining
gaps. In: Progress Towards Novel Testing Strategies for in Vitro Assessment of Allergens. Transworld
Research Network, Kerala, India, pp 1-13, 2011.
Buck J, Hattersley S and Kimber I. Food allergy – science and policy needs – The UK Food Standards
Agency Research Programme. Toxicology 278:319-325, 2010.
Corsini E, Oukka M, Pieters R, Kerkvliet NI, Ponce R and Germolec DR. Alterations in regulatory T-cells:
Rediscovered pathways in immunotoxicology. J Immunotoxicol 8:251-257, 2011.
DeWitt J, Peden-Adams M, Keller J and Germolec D. The immunotoxicity of perfluorinated compounds:
Recent developments. Toxicol Pathol doi: 10.1177/0192623311427709, 2011.
DeWitt J, Peden-Adams M, Keil D and Dietert R. Current status of developmental immunotoxicity: Early-life
patterns and testing. Toxicol Pathol doi:10.1177/0192623311428473, 2011.
Diamond G, Ryan LK. ß-Defensins: What are they REALLY doing in the oral cavity? Oral Diseases 17:628635, 2011.
Eussen SRBM, Verhagen H, Klungel OH, Garssen J, van Loveren H, van Kranen HJ and Rompelberg CJM.
Functional foods and dietary supplements: Products at the interface between pharma and nutrition. Eur J
Pharmacol 668:52-59, 2011.
Hartung T, Blaauboer BJ, Bosgra S, Carney E, Coenen J, Conolly RB, Corsini E, Green S, Faustman EM,
Gaspari A, Hayashi M, Wallace Hayes A, Hengstler JG, Knudsen LE, Knudsen TB, McKim JM, Pfaller W
and Roggen EL. An expert consortium review of the EC-commissioned report "Alternative (non-animal)
methods for cosmetics testing: current status and future prospects - 2010". ALTEX. 28:183-209, 2011.
Kawabata T, Weaver J, Thomas D, Rowe M, Wang F, Kamperschroer C and Haggerty H. Summary ofroundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans. J
Immunotoxicol 2012 early on-line DOI: 10.3109/1547691X.2011.635166.
Ponce, RA. Safety assessment of immunomodulatory biologics: The promise and challenges of regulatory Tcell modulation. J Immunotoxicol 8:389-397, 2011.
van der Veen JW, Vandebriel RJ, van Loveren H and Ezendam J. Keratinocytes, Innate Immunity and Allergic
Contact Dermatitis – Opportunities for the Development of In Vitro Assays to Predict the Sensitizing Potentialof Chemicals. In: Contact Dermatitis, ImTech, 2011

January 201214

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications

Vandebriel R, Callant Cransveld C, Crommelin D, Diamant Z, Glazenburg B, Joos F, Kuper F, Natsch A,
Nijkamp F, Noteborn H, Pieters R, Roberts D, Roggen E, Rorije E, Seed M, Sewald K, van den Heuvel R, vanEngelen J, Verstraelen S and van Loveren H. Respiratory sensitization: Advances in assessing the risk of
respiratory inflammation and irritation. Toxicol In Vitro 25: 1251-1258, 2011.

Books/ Book Chapters
Vandebriel RJ, van Loveren H, Baken KA and Pennings JLA. Immunotoxicogenomics: A systems approach.
In: General, Applied and Systems Toxicology, John Wiley & Sons, Ed. pp 1-8, 2011.

January 201215

Immunotoxicology Specialty Section